Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.

Vardeny O, Nicholas G, Andrei A, Buhr KA, Hermanson MP, Moran JJ, Detry MA, Stein JH.

Am J Hypertens. 2012 Aug;25(8):920-6. doi: 10.1038/ajh.2012.54. Epub 2012 May 31.

3.

Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.

Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C.

Vasc Health Risk Manag. 2007;3(1):31-7. Review.

4.

Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.

Bauman JL, Talbert RL.

J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):117-28. Review.

PMID:
15309248
5.

Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.

Maack C, Elter T, Böhm M.

Congest Heart Fail. 2003 Sep-Oct;9(5):263-70. Review.

6.

Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.

Talbert RL.

Heart Fail Rev. 2004 Apr;9(2):131-7. Review.

PMID:
15516861
7.

Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.

Briasoulis A, Palla M, Afonso L.

Am J Cardiol. 2015 Apr 15;115(8):1111-5. doi: 10.1016/j.amjcard.2015.01.545. Epub 2015 Jan 31. Review.

PMID:
25708861
8.

Carvedilol in hypertension treatment.

Stafylas PC, Sarafidis PA.

Vasc Health Risk Manag. 2008;4(1):23-30. Review.

9.

[Efficacy and safety of metoprolol CR/XL: confidence based on proofs].

Skibitskiĭ VV.

Kardiologiia. 2008;48(9):62-5. Review. Russian. No abstract available.

PMID:
18991824

Supplemental Content

Support Center